CTOs on the Move

Optinose

www.optinose.com

 
We are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Our first commercial product, XHANCE® (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing our proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). In September 2017, the U.S. Food and Drug Administration (FDA) approved XHANCE for the treatment of nasal polyps in patients 18 years of age or ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.optinose.com
  • 1020 Stony Hill Road Suite 300
    Yardley, PA USA 19067
  • Phone: 267.364.3500

Executives

Name Title Contact Details
Robert Bell
Director of IT Profile

Similar Companies

Corium

Corium is a commercial-stage biopharmaceutical company that is leading the development and commercialization of central nervous system (CNS) healthcare therapies that provide clinicians with important treatment options for patients, their families, and their caregivers. Collaborating with some of the world`s largest pharmaceutical and consumer product companies, we have a track record and depth of experience in taking products from concept, through development, to manufacturing and final commercialization.

Prism Health North Texas

PHNTX is the largest local nonprofit HIV/AIDS service organization in North Texas providing HIV care, free STI and HIV testing, transgender care, and more.

Cognito Therapeutics

Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer`s disease. Cognito has received FDA Breakthrough Device Designation for the treatment of Alzheimer`s disease and expects to start pivotal studies in 2022. The company`s technology was based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and Ed Boyden at MIT.

Norwich Pharmaceuticals

Norwich Pharmaceuticals, Inc. is a Norwich, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Banziger Systems

Banziger Systems is a Emeryville, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.